Oruka Therapeutics, Inc.
ORKAHeld by 9 specialist biotech funds
High Convergence9 funds opened new positions. Next phase2 readout (ORKA-001 Induction Dose): Apr 2026. Short interest: 17.4% of float.
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.